A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)

被引：0
|
作者：
Fountzilas, Christos
Ko, Andrew H.
Borazanci, Erkut Hasan
D'Olimpio, James Thomas
Hecht, J. Randolph
Tang, Shou-Ching
Shields, Anthony F.
Salkeni, Mohamad Adham
Michelson, Glenn
Cho, Gene
Liganor, Lorna
Cho, Sangsook Ahn
Walker, Evan Justin
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens, San Francisco, CA USA
[3] HonorHealth Res Inst, Scottsdale, AZ USA
[4] Clin Res Alliance, Westbury, NY USA
[5] UCLA, Jonsson Comprehens Canc Ctr, Santa Monica, CA USA
[6] LSU Sch Med, New Orleans, LA USA
[7] Karmanos Canc Inst, Detroit, MI USA
[8] Virginia Canc Specialists VCS Res Inst, Fairfax, VA USA
[9] CG Pharmaceut Inc, Orinda, CA USA
[10] Univ Calif San Francisco, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4206
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Walker, Evan Justin
    Fountzilas, Christos
    Borazanci, Erkut Hasan
    Shields, Anthony F.
    D'Olimpio, James Thomas
    Hecht, J. Randolph
    Tang, Shou-Ching
    Michelson, Glenn
    Liganor, Lorna
    Cho, Sangsook Ahn
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 666 - 666
  • [2] Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study.
    Fountzilas, Christos
    Ko, Andrew H.
    Borazanci, Erkut Hasan
    D'Olimpio, James Thomas
    Hecht, Joel R.
    Tang, Shou-Ching
    Shields, Anthony F.
    Salkeni, Mohamad Adham
    Michelson, Glenn C.
    Liganor, Lorna
    Cho, Gene
    Cho, Sangsook Ahn
    Walker, Evan Justin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [3] A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed on first-line FOLFIRINOX chemotherapy (CT)
    Walker, Evan Justin
    Borazanci, Erkut Hasan
    Botrus, Gehan
    Fountzilas, Christos
    Hecht, J. Randolph
    Kasi, Anup
    Mettu, Niharika B.
    Pant, Shubham
    Michelson, Glenn
    Cho, Gene
    Cho, Sangsook Ahn
    Liganor, Lorna
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, W.
    Kornek, G.
    Prager, G.
    Stranzl, N.
    Laengle, F.
    Schindl, M.
    Friedl, J.
    Klech, J.
    Roethlin, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [5] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, Werner
    Kornek, Gabriela
    Prager, Gerald
    Stranzl, Nadja
    Laengle, Friedrich
    Schindl, Martin
    Friedl, Josef
    Klech, Julia
    Roethlin, Sabine
    Zielinski, Christoph
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (02) : 234 - 238
  • [6] Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:: a randomized phase II trial
    Scheithauer, W
    Schüll, B
    Ulrich-Pur, H
    Schmid, K
    Raderer, M
    Haider, K
    Kwasny, W
    Depisch, D
    Schneeweiss, B
    Lang, F
    Kornek, GV
    ANNALS OF ONCOLOGY, 2003, 14 (01) : 97 - 104
  • [7] Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer
    Vukelja, S.
    Richards, D.
    Campos, L. T.
    Bedell, C.
    Hagenstad, C.
    Hyman, W.
    Letzer, J.
    Gardner, L.
    Sportelli, P.
    Nemunaitis, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer
    Xu, Binghe
    Zhang, Pin
    Sun, Tao
    Zhang, Qingyuan
    Jiang, Zefei
    Yuan, Zhongyu
    Wang, Xiaojia
    Cui, Shude
    Teng, Yuee
    Hu, Xi-Chun
    Yang, Junlan
    Pan, Hongming
    Tong, Zhongsheng
    Li, Huiping
    Yao, Qiang
    Wang, Yongsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
    Reni, M.
    Zanon, S.
    Pircher, C.
    Chiaravalli, M.
    Macchini, M.
    Peretti, U.
    Mazza, E.
    Balzano, G.
    Passoni, P.
    Nicoletti, R.
    Arcidiacono, P. G.
    Pepe, G.
    Doglioni, C.
    Romi, S.
    Ceraulo, D.
    Falconi, M.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines
    Campone, Mario
    Dobrovolskaya, Natalya
    Tjulandin, Serjei
    Chen, Shin-Chen
    Fourie, Sameul
    Mefti, Fawzia
    Konstantinova, Maria
    Lefresne, Florence
    Meheust, Nadege
    Jassem, Jacek
    BREAST JOURNAL, 2013, 19 (03): : 240 - 249
12345